ライフサイエンスコーパス: drug delivery system

1 tract (e.g., solid dispersions, lipid-based drug delivery systems).

2 responsive release behavior of the on-demand drug delivery system.

3 general, emphasized and investigated in each drug delivery system.

4 le physicochemical properties for a targeted drug delivery system.

5 onstrate the promise of a gel depot as an IP drug delivery system.

6 agement of lung cancer requires an efficient drug delivery system.

7 vide a platform to develop novel anti-cancer drug delivery system.

8 gs are a promising multifunctional antitumor drug delivery system.

9 ing a salient feature of this tumor-targeted drug delivery system.

10 a new nanoformulation for use as an anti-TB drug delivery system.

11 1B transporters is affected by the choice of drug delivery system.

12 ovel approach for cell-based therapeutic and drug delivery system.

13 dicine - specifically a HPMA copolymer-based drug delivery system.

14 indicating their potential as an anticancer drug delivery system.

15 rats using a modified vibrating mesh aerosol drug delivery system.

16 ecent advances for the development of ocular drug delivery systems.

17 ngineering to high-performance filtering and drug delivery systems.

18 vitro drug release kinetics of nanoparticle drug delivery systems.

19 novel approach for targeted supersaturating drug delivery systems.

20 limitations of drugs as well as conventional drug delivery systems.

21 e design of the next-generation of nanoscale drug delivery systems.

22 g MDR and recent progress of combined NO and drug delivery systems.

23 possible applications in drug synthesis and drug delivery systems.

24 l research and development led to commercial drug delivery systems.

25 ssible when combined with molecular-targeted drug delivery systems.

26 echnology, nanomedicine, and many nano-sized drug delivery systems.

27 problem, researchers are investigating novel drug delivery systems.

28 ducts, ranging from processed foods to novel drug delivery systems.

29 ing cellular uptake and nuclear targeting of drug delivery systems.

30 applicability of dSTORM for use in studying drug delivery systems.

31 py, oral drug delivery systems, and biologic drug delivery systems.

32 m demonstrated herein are key for successful drug delivery systems.

33 explored for endocytosis and transcytosis of drug delivery systems.

34 ising potential for developing the efficient drug delivery systems.

35 lymer science that enables precise design of drug delivery systems.

36 o improve the poor clinical success of local drug delivery systems.

37 e promising to develop diagnostic probes and drug delivery systems.

38 on of clinically-relevant controlled release drug delivery systems.

39 ved accelerated in vivo release of polymeric drug delivery systems.

40 g bioavailability is a key consideration for drug delivery systems.

41 iew the mechanisms by which UV light affects drug delivery systems.

42 use for remote control of nanomedicines and drug delivery systems.

43 nce of the clinical and commercial impact of drug delivery systems.

44 rtant tools for developing clinically useful drug delivery systems.

45 d be modified to home to and refill hydrogel drug delivery systems.

46 ereof as potential building blocks for novel drug delivery systems.

47 velop successful and cost-effective EV-based drug delivery systems.

48 valuable strategy for the development of new drug delivery systems.

49 tools allow new ways to manufacture and test drug delivery systems.

50 c applications of cellular hitchhiking-based drug delivery systems.

51 gical processes and developing intracellular drug delivery systems.

52 engineering, development of microarrays, and drug delivery systems.

53 3D printed drug products and nanofiber-based drug delivery systems.

54 rs design safer and more efficient nanobased drug delivery systems.

55 ach to fabricate bespoke medical devices and drug delivery systems.

56 ation of classical dosage forms and advanced drug delivery systems.

57 in interactions and the development of novel drug delivery systems.

58 thus conducive for use in the preparation of drug delivery systems.

59 efficacy and safety of current therapies and drug delivery systems.

60 gely limited in scope in regard to polymeric drug delivery systems.

61 ts limitations in the context of anti-cancer drug delivery systems.

62 orward toward the development of implantable drug-delivery systems.

63 iomolecules is crucial for improving current drug-delivery systems.

64 st chemistry of pharmaceuticals in nanosized drug-delivery systems.

65 lines and perspectives to achieve efficient drugs delivery systems.

66 cterization of solid microparticles as nasal drug delivery systems able to increase the nose-to-brain

67 mprehensively describes various NPs-mediated drug delivery systems according to different NPs species

68 strated the antibacterial capability of this drug delivery system against Escherichia coli by the dis

69 Functionalized drug delivery systems against malignant lung metastasis

70 Balloon-based drug delivery systems allow localized application of dru

71 The drug delivery system also comprises a semi-automatic rec

72 context, we review recent development of PTX drug delivery systems and analyze the design principles

73 bacteria-enabled systems including biohybrid drug delivery systems and biohybrid mobile sensor networ

74 other applications, such as optoelectronics, drug delivery systems and even lithium-ion batteries.

75 Nano-fabricated smart drug delivery systems and implantable drug loaded biomat

76 rates the development of magnetically guided drug delivery systems and its potential on efficient ant

77 (i.e. biosensors, microfluidic bioreactors, drug delivery systems and Lab-On-Chip).

78 ge the beneficial features of both polymeric drug delivery systems and liposomes in a single nanocarr

79 s, such as new symptomatic drugs, innovative drug delivery systems and novel surgical interventions g

80 y, drug delivery for localized therapy, oral drug delivery systems, and biologic drug delivery system

81 probes, prototypes of smart therapeutics and drug delivery systems, and explore the future challenges

82 d delivery of bioactive moieties, anticancer drug delivery systems, and theranostics (i.e., real-time

83 jority of clinically used nanoparticle-based drug delivery systems are based on the EPR effect, and,

84 As the physicochemical properties of drug delivery systems are governed not only by the mater

85 ation and accumulation of nanoparticle-based drug delivery systems are highly dependent on the partic

86 New drug delivery systems are highly needed in research and

87 On-demand drug delivery systems are highly promising to control th

88 Tumor-targeted drug delivery systems are promising for their advantages

89 Drug delivery systems are required for drug targeting to

90 Development and validation of exosome-based drug delivery systems are the focus of this review.

91 Drug delivery systems are widely researched and develope

92 Micelles, as a class of drug delivery systems, are underrepresented among United

93 e employed various free radical-incorporated drug delivery systems as an approach to target biofilm f

94 Transdermal drug delivery systems as films not only avoids first-pas

95 introduce these interactions to the micellar drug delivery systems, as well as the effects of these i

96 g method for preclinical assessment of novel drug delivery systems at therapeutic doses in models of

97 Herein we developed a nanoparticle drug delivery system based on the assembly of surface-mo

98 one-pot process led to be the most favorable drug delivery system based on the release kinetics point

99 Drug delivery systems based on electrospun fibers have b

100 The development of drug delivery systems based on well-defined polymer nano

101 A "relay drug delivery" system based on two distinct modules, whi

102 Self-powered drug-delivery systems based on conductive polymers (CPs)

103 extensively explored as a means to increase drug delivery systems' biocompatibility and biodegradati

104 world bioelectronics applications, including drug delivery systems, biosensing and electrical modulat

105 biomaterial in many applications, including drug-delivery systems, bone-graft fillers and medical de

106 f the nanosponges not only as a dual release drug delivery system but also enabling a regulated metab

107 ectrospun nanofibers based "fast dissolving" drug delivery systems by employing variety of polymers,

108 and can overcome many drawbacks of existing drug delivery systems by virtue of tunable compositions,

109 ngs provide proof of concept that this novel drug delivery system can precisely reverse the multidrug

110 understood so that the future development of drug delivery systems can be accelerated and prolific ag

111 ring the pH differences in the body, various drug delivery systems can be designed by utilizing smart

112 The advanced drug delivery systems can improve the macrophage-based t

113 The implantable drug-delivery system can be powered with a TENG device r

114 st and smart "all-in-one" nanoparticle-based drug delivery system capable of overcoming biological ba

115 is required to optimize and design liposomal drug delivery systems capable of controllable release ta

116 es include skeletal tissues and biominerals, drug delivery systems, catalysts, sensors, separation me

117 of probucol (PB) by constructing a combined drug delivery system (CDDS) composed of nanostructured l

118 The present study reports a drug delivery system comprising nanostructured lipid car

119 A bioinspired cocoon-like anticancer drug delivery system consisting of a deoxyribonuclease (

120 In this study, electrospun membrane drug delivery systems consisting of the antibiotic cipro

121 The composite drug delivery system consists of highly-textured superhy

122 Light-controlled drug delivery systems constitute an appealing means to d

123 ortant immune functions, and accumulation of drug delivery systems could have significant implication

124 increasing industrial interest in silk-based drug delivery systems currently at various stages of the

125 e and commonly used therapy, introduce local drug delivery systems currently on the market or in the

126 ting molecules other than VEGF and using new drug-delivery systems currently are being developed and

127 Further, we constructed photoresponsive dual drug delivery system (DDS) to release two different anti

128 Advanced drug delivery systems (DDS) enhance treatment efficacy o

129 Over the last several decades, numerous drug delivery systems (DDS) have been developed in order

130 their importance as site-specific controlled drug delivery systems (DDSs) and has encouraged their ra

131 nal clearable gold nanoparticle (AuNP)-based drug delivery systems (DDSs) in the delivery of doxorubi

132 Spurred by newly developed drug delivery systems (DDSs), side effects of cancer che

133 Among drug delivery systems (DDSs), smart nanocarriers that re

134 carriers are one kind of these newly emerged drug delivery systems (DDSs), which enable drugs to rapi

135 norganic nanocarriers have been explored for drug delivery systems (DDSs).

136 Systemically injected drug delivery systems distribute into various organs and

137 e adjunctive use of 0.5% AZM as a controlled drug delivery system enhances the clinical outcome.

138 rmacological efficacy of a female controlled drug delivery system (FcDDS) intended for prevention of

139 Drug delivery systems featuring first-order release kine

140 PSMA peptide-targeted EMs can be a promising drug delivery system for advanced PC.

141 Our aim was to develop a drug delivery system for angiotensin-(1-9).

142 ch and the uses of casein-based hydrogels as drug delivery system for both hydrophobic and hydrophili

143 The application of nanocarriers as drug delivery system for chemotherapeutic drugs has beco

144 vel nucleoside-based supramolecular gel as a drug delivery system for proteins with different propert

145 Thus, they represent a potent drug delivery system for the application in a variety of

146 We present a drug delivery system for the GI tract based on coating s

147 that polymeric microspheres are suitable as drug delivery system for the sustained systemic delivery

148 To develop a biodegradable polymeric drug delivery system for the treatment of ovarian cancer

149 the desired characteristics of an effective drug delivery system for the treatment of pulmonary dise

150 Is) have shown promise as a sustained, local drug delivery system for therapeutics in a variety of ap

151 orward for developing a locally administered drug delivery system for treating DCIS, for which no pri

152 ents will enable discovery of more effective drug delivery systems for brain.

153 on process has been studied to develop smart drug delivery systems for decades.

154 id based nanocarriers can serve as bioactive drug delivery systems for effective treatment of lysosom

155 focus on in vivo validation of such magnetic drug delivery systems for first time, we selected cispla

156 he application of dendritic glycopolymers in drug delivery systems for gene transfection but also as

157 udies and important clinical trials of novel drug delivery systems for glaucoma and evaluates the pot

158 the application of free radical-incorporated drug delivery systems for inhibiting biofilm formation a

159 disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.

160 Currently available drug delivery systems for oral diseases suffer from shor

161 loads for antibody-drug conjugates and other drug delivery systems for personalized targeted cancer c

162 g this non-covalent interaction in nanoscale drug delivery systems for pharmaceutical agents, includi

163 plication of MEs as extravascular injectable drug delivery systems for sustained release.

164 delivery, and tissue engineering.The use of drug delivery systems for the gastrointestinal tract has

165 s of lesion location, there are no effective drug delivery systems for the therapy of TAD.

166 pecifically nanoparticles and nanofibers, as drug delivery systems for topical and transdermal applic

167 We report here a novel nano-assembled drug-delivery system, formed by multivalent host-guest i

168 No periadventitial drug delivery system has reached clinical application.

169 potential for use of polymers in controlled drug delivery systems has been long recognized.

170 s and synthetic nanoparticles, many advanced drug delivery systems have been developed that adopt the

171 ercome this barrier, nanoparticle (NP) based drug delivery systems have been reported.

172 Numerous local drug delivery systems have been studied to overcome the

173 Local drug delivery systems have been widely explored to reduc

174 Cell-based drug delivery systems have generated an increasing inter

175 Oral drug delivery systems have multiple goals, assessing and

176 For more than 60years drug delivery systems have produced numerous controlled

177 The electrospun nanofiber based drug delivery systems have shown tremendous advancements

178 localized nature of these chronic diseases, drug delivery systems have the potential to enhance ther

179 Zero-order drug delivery systems have the potential to overcome the

180 rtheless, so far imaging-guided photothermal drug-delivery systems have been developed with limited s

181 properties of these novel nanoconstructs as drug-delivery systems highlight the potential of this ap

182 e increasingly attracted to exploit those as drug delivery systems, highly efficient photothermal mod

183 Clinical outcomes from nano-sized drug delivery systems, however, have indicated that EPR

184 he development of implantable and insertable drug delivery systems (IDDS) from their early stage in t

185 The nanoparticles (NPs)-mediated drug delivery systems improve drug solubility and bioava

186 Using a novel biomaterial-based drug delivery system in the form of a hydrogel to achiev

187 be used as a novel and effective target for drug delivery system in tumor cells using chemically mod

188 strategy for engineering stimuli-responsive drug delivery systems in a bioinspired and synergistic f

189 Nanoparticles are emerging as targeted drug delivery systems in chronic inflammatory disorders.

190 ategies to overcome these challenges include drug delivery systems in conjunction with other chemical

191 This review showcases local drug delivery systems in different inflammatory diseases

192 In addition, the loaded drug delivery systems in fibrin scaffolds decreased CSPG

193 roach can be used to monitor accumulation of drug delivery systems in preclinical and clinical studie

194 therapy to [60]fullerene nanoparticle-based drug delivery systems in targeting the micro-vasculature

195 crucial parameter for their potential use as drug delivery systems in vivo.

196 methods used to design and evaluate targeted drug delivery systems in vivo.

197 ped a two-component, two-step, pre-targeting drug delivery system integrated with image guidance to c

198 create a novel sustained-release intraocular drug delivery system (IODDS) for the treatment of glauco

199 A closed-loop implantable drug delivery system is an ideal solution to minimize th

200 This novel drug delivery system is comprised of a thermoresponsive

201 Developing an advanced nucleic acid drug delivery system is of great significance in order t

202 Targeting drug delivery systems is crucial to reducing the side ef

203 apeutic efficacy of conventional transdermal drug delivery systems is often limited because the HS ti

204 The proposed nanoparticulate drug-delivery system is designed for the oral administra

205 lf-powered on-skin iontophoretic transdermal drug-delivery system is developed as an on-skin chemical

206 erator (TENG)-based self-powered implantable drug-delivery system is presented.

207 neering and integration with biomaterials or drug delivery systems, is examined.

208 lized delivery of rapamycin via a biomimetic drug delivery system, it is possible to reduce vascular

209 These results suggested that this coaxial drug-delivery system loaded with Ade provided a promisin

210 f zero-order release systems, self-regulated drug delivery systems, long-term depot formulations, and

211 In this regard, nanoscale drug delivery systems (Nano-DDS) have led to the expecta

212 he next generation of bacteriocin nano-sized drug delivery systems (Nano-DDS).

213 unities for the application of nano targeted drug-delivery systems (Nano-TDDS) in cancer therapy.

214 (NP) entries as core components of nanoscale drug delivery systems (NDDSs) by making use of analytica

215 In particular, nanoparticle-based drug delivery systems not only facilitate the delivery o

216 onstructed a natural-lipid (NL) nanoparticle drug delivery system (NP-DDS) to encapsulate 6-shogaol a

217 limitations of retinoids, the development of drug delivery systems offers several advantages for clin

218 Effective targeted drug delivery systems often rely on external stimuli to

219 or investigating the intramucus transport of drug delivery systems or food nanoparticles.

220 of membranes, the dynamics of vesicle-based drug delivery systems, or, more generally, the behaviour

221 as been utilized in developing polymer-based drug delivery systems over the past 10years.

222 citing approach to develop novel imaging and drug delivery systems, owing to the ease with which thes

223 Fibrin scaffolds embedded with the drug delivery systems (PLGA microspheres and lipid micro

224 rface chemistry of polymeric nanoparticulate drug delivery systems (PNDDS) on their adsorption dynami

225 e to produce biofunctional nanovesicle-based drug delivery systems potentially applied to treat vario

226 ne in cancer is the development of effective drug delivery systems, primarily nanoparticles.

227 pical DFO administration using a transdermal drug delivery system prior to and immediately following

228 logies, including actuators, motion sensors, drug delivery systems, projection displays, etc.

229 Nanoparticle-based drug delivery systems provide a highly promising approac

230 Injectable, long-acting drug delivery systems provide effective drug concentrati

231 This novel LGFU-responsive drug delivery system provides a simple and remote approa

232 Sustained release drug delivery systems remain a major clinical need for s

233 tly, MCTS have also been widely exploited in drug delivery system research for comprehensive study of

234 ated to their applications in tumor-targeted drug delivery system research.

235 rowing use of agarose-based biomaterials for drug delivery systems resulted in rapid growth in the nu

236 , thereby contributing to the development of drug delivery systems satisfying clinical requirements.

237 he potential application of self-emulsifying drug delivery system (SEDDS), that enhances oral absorpt

238 e correct administration procedure, suitable drug delivery system, selection of effective and safe do

239 jective of this study was to develop a novel drug delivery system, solid lipid nanoparticle (SLN), ca

240 evelopment of plant virus-based materials as drug delivery systems; specifically, this work focuses o

241 Overall, implementation of local drug delivery systems such as this could reduce the need

242 In addition, new drug delivery systems, such as implants and transdermal

243 Local drug delivery systems, such as in situ forming implants

244 Advanced biomaterials and drug delivery systems, such as nanoparticles and the use

245 A drug delivery system suitable for systemic administratio

246 We hypothesize that a three-drug nanoscale drug delivery system, tailored for lymphatic uptake, adm

247 have the potential to be used as anti-cancer drug delivery systems targeted for the lungs.

248 DK inhibitor conjugates with folic acid as a drug-delivery system targeting folate receptors.

249 IF-1alpha activity we designed a transdermal drug delivery system (TDDS) containing the FDA-approved

250 tly published a preclinical proof of concept drug delivery system (TDDS) which showed that transderma

251 in-adhesive (DIA) type estradiol transdermal drug delivery systems (TDDS).

252 In conclusion, we developed a biodegradable drug delivery system that accelerated healing processes

253 In conclusion, we have developed a modular drug delivery system that can be targeted to cell types

254 in, we report on an effective brain-targeted drug delivery system that combines a robust red blood ce

255 ligands within liposomes, a well-established drug delivery system that enables payload stability and

256 fine-tuning the PK parameters of a targeted drug delivery system that exploits the benefits of both

257 this manuscript, we present a novel micellar drug delivery system that is not only capable of releasi

258 with drug-eluting beads (DEB-TACE), a novel drug delivery system that produces a slow and sustained

259 s (LTSLs) are a promising stimuli-responsive drug delivery system that rapidly releases DOX in respon

260 This study employs a drug delivery system that specifically delivers the PDE4

261 ntial to revolutionize medicine by designing drug delivery systems that are both efficacious and high

262 ed to their development as actively targeted drug delivery systems that expand on and improve current

263 he absorption of orally dosed compounds from drug delivery systems that generate supersaturation with

264 will highlight some of the examples of novel drug delivery systems that have undergone such translati

265 Here we present a targeted, non-invasive drug delivery system to decrease inflammation in an oste

266 edles (MNs) have been proposed as a suitable drug delivery system to facilitate intradermal delivery

267 porating NLC can be exploited as a promising drug delivery system to improve oral bioavailability and

268 her development of a sustainable intraocular drug delivery system to protect RGCs, which may be appli

269 tered biodegradable nanoparticles (NPs) as a drug delivery system to the lesion site in rat and pig c

270 ies that may be incorporated into these oral drug delivery systems to further enhance drug uptake.

271 eability may afford opportunities to develop drug delivery systems to improve efficacy and reduce tox

272 the importance in translating liposome-based drug delivery systems to other molecules and cargo.

273 iomedical applications ranging from advanced drug delivery systems to tissue engineering.

274 rtunities to use site-directed, programmable drug delivery systems to treat auditory and vestibular d

275 tes are promising candidates for long-acting drug delivery systems to treat chronic diseases.

276 This study aimed to fabricate an efficient drug-delivery system to reduce the undesirable side effe

277 ential to provide a new level of control for drug delivery systems, tumor detection markers, biosenso

278 dy, we demonstrate that a novel transvaginal drug delivery system (TVDS) is capable of delivering pep

279 hylene vinyl acetate (EVA) ring transvaginal drug delivery system (TVDS).

280 s as candidates in applications ranging from drug delivery systems, up to artificial organelles, or a

281 interaction, we created a nanovesicle-based drug delivery system using nitrogen cavitation which rap

282 e aim to develop an RGC-targeted intraocular drug delivery system using unimolecular micelle nanopart

283 Targeted drug delivery systems using nanoparticle nanocarriers of

284 drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v) pulmonary drug delivery, (vi)

285 The magnetically guided drug delivery system was successfully developed by utili

286 MCM-41, for prolonged release of atenolol in drug delivery systems was investigated both experimental

287 Development of new controlled drug delivery systems was very productive during the per

288 y higher in mice receiving the targeted nano-drug delivery system when compared to non-targeted syste

289 toxins may be increased by utilization of a drug delivery system which provides selective release of

290 there is an urgent need to develop improved drug delivery systems which have potential to cross impa

291 The development of anticancer drug delivery systems which retain or enhance the cytoto

292 onstrate that [S]-PM is a promising targeted drug delivery system, which can be advanced for the trea

293 release system provides a more sophisticated drug delivery system, which can differentiate ATP levels

294 pplicability of a novel nanotechnology-based drug delivery system, which induces recovery of diaphrag

295 hance the biological outcome of nanoparticle drug delivery systems, which often suffer from poor circ

296 oth synthetic nanocarriers and cell-mediated drug delivery systems while avoiding their limitations.

297 gies to equip nanocarriers of the controlled drug delivery systems with MB-based fluorescence imaging

298 , have led to a rapidly increasing number of drug delivery systems with potential for spatiotemporall

299 The interaction of drug delivery systems with tissues is key for their appl

300 rapy can be achieved by designing a targeted drug-delivery system with high stability during circulat